152 related articles for article (PubMed ID: 38096681)
21. Comparison of antibacterial activities of polymyxin B and colistin against multidrug resistant Gram negative bacteria.
Doymaz MZ; Karaaslan E
Infect Dis (Lond); 2019 Sep; 51(9):676-682. PubMed ID: 31298061
[No Abstract] [Full Text] [Related]
22. Polymyxin-based fluorescent probes to combat Gram-negative antimicrobial resistance.
Han X; Cui AL; Yang HX; Wu L; Wei R; Liu Q; Li ZR; Hu HY
Talanta; 2023 Aug; 260():124576. PubMed ID: 37148689
[TBL] [Abstract][Full Text] [Related]
23. PmxPred: A data-driven approach for the identification of active polymyxin analogues against gram-negative bacteria.
Wang X; Patil N; Li F; Wang Z; Zhan H; Schmidt D; Thompson P; Guo Y; Landersdorfer CB; Shen HH; Peleg AY; Li J; Song J
Comput Biol Med; 2024 Jan; 168():107681. PubMed ID: 37992470
[TBL] [Abstract][Full Text] [Related]
24.
Duncan LR; Wang W; Sader HS
Antimicrob Agents Chemother; 2022 May; 66(5):e0013922. PubMed ID: 35475635
[TBL] [Abstract][Full Text] [Related]
25. The polymyxin derivative NAB739 is synergistic with several antibiotics against polymyxin-resistant strains of Escherichia coli, Klebsiella pneumoniae and Acinetobacter baumannii.
Tyrrell JM; Aboklaish AF; Walsh TR; Vaara T; Vaara M
Peptides; 2019 Feb; 112():149-153. PubMed ID: 30586602
[TBL] [Abstract][Full Text] [Related]
26. Development of dilipid polymyxins: Investigation on the effect of hydrophobicity through its fatty acyl component.
Domalaon R; Berry L; Tays Q; Zhanel GG; Schweizer F
Bioorg Chem; 2018 Oct; 80():639-648. PubMed ID: 30053708
[TBL] [Abstract][Full Text] [Related]
27. Design of Next Generation Polymyxins with Lower Toxicity: The Discovery of SPR206.
Brown P; Abbott E; Abdulle O; Boakes S; Coleman S; Divall N; Duperchy E; Moss S; Rivers D; Simonovic M; Singh J; Stanway S; Wilson A; Dawson MJ
ACS Infect Dis; 2019 Oct; 5(10):1645-1656. PubMed ID: 31525992
[TBL] [Abstract][Full Text] [Related]
28. Polymyxin B in Combination with Enrofloxacin Exerts Synergistic Killing against Extensively Drug-Resistant Pseudomonas aeruginosa.
Lin YW; Yu HH; Zhao J; Han ML; Zhu Y; Akter J; Wickremasinghe H; Walpola H; Wirth V; Rao GG; Forrest A; Velkov T; Li J
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29632010
[TBL] [Abstract][Full Text] [Related]
29. Agents of Last Resort: An Update on Polymyxin Resistance.
Yang Q; Pogue JM; Li Z; Nation RL; Kaye KS; Li J
Infect Dis Clin North Am; 2020 Dec; 34(4):723-750. PubMed ID: 33011049
[TBL] [Abstract][Full Text] [Related]
30. Polymyxin-resistant clinical isolates of Escherichia coli.
Urban C; Tiruvury H; Mariano N; Colon-Urban R; Rahal JJ
Antimicrob Agents Chemother; 2011 Jan; 55(1):388-9. PubMed ID: 21041507
[TBL] [Abstract][Full Text] [Related]
31. Lethal effect of complement and lysozyme on polymyxin-treated, serum-resistant gram-negative bacilli.
Fierer J; Finley F
J Infect Dis; 1979 Oct; 140(4):581-9. PubMed ID: 229175
[TBL] [Abstract][Full Text] [Related]
32. Resveratrol enhances the antimicrobial effect of polymyxin B on Klebsiella pneumoniae and Escherichia coli isolates with polymyxin B resistance.
Liu L; Yu J; Shen X; Cao X; Zhan Q; Guo Y; Yu F
BMC Microbiol; 2020 Oct; 20(1):306. PubMed ID: 33045992
[TBL] [Abstract][Full Text] [Related]
33. Synergistic antibacterial and anti-biofilm activities of resveratrol and polymyxin B against multidrug-resistant Pseudomonas aeruginosa.
Qi L; Liang R; Duan J; Song S; Pan Y; Liu H; Zhu M; Li L
J Antibiot (Tokyo); 2022 Oct; 75(10):567-575. PubMed ID: 35999263
[TBL] [Abstract][Full Text] [Related]
34. Suppression of planktonic and biofilm of Escherichia coli by the synergistic lantibiotics-polymyxins combinations.
Polyudova T; Lemkina L; Eroshenko D; Esaev A
Arch Microbiol; 2024 Mar; 206(4):191. PubMed ID: 38520490
[TBL] [Abstract][Full Text] [Related]
35. [Advances in the diagnosis and treatment strategy of polymyxin resistant
Chen YX; Xu YP; Zhu YG; Qu JM
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Aug; 46(8):813-818. PubMed ID: 37536993
[TBL] [Abstract][Full Text] [Related]
36. Clinical translation of polymyxin-based combination therapy: Facts, challenges and future opportunities.
Zhang X; Guo F; Shao H; Zheng X
J Infect; 2017 Feb; 74(2):118-130. PubMed ID: 27998750
[TBL] [Abstract][Full Text] [Related]
37. Polymyxin Derivatives that Sensitize Gram-Negative Bacteria to Other Antibiotics.
Vaara M
Molecules; 2019 Jan; 24(2):. PubMed ID: 30641878
[TBL] [Abstract][Full Text] [Related]
38. Teaching 'old' polymyxins new tricks: new-generation lipopeptides targeting gram-negative 'superbugs'.
Velkov T; Roberts KD; Nation RL; Wang J; Thompson PE; Li J
ACS Chem Biol; 2014 May; 9(5):1172-7. PubMed ID: 24601489
[TBL] [Abstract][Full Text] [Related]
39. Strategies to Overcome Antimicrobial Resistance (AMR) Making Use of Non-Essential Target Inhibitors: A Review.
Annunziato G
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31766441
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of Antimicrobial Effects of a New Polymyxin Molecule (SPR741) When Tested in Combination with a Series of β-Lactam Agents Against a Challenge Set of Gram-Negative Pathogens.
Mendes RE; Rhomberg PR; Lister T; Cotroneo N; Rubio A; Flamm RK
Microb Drug Resist; 2020 Apr; 26(4):319-328. PubMed ID: 31596663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
